- Home
- BDL vs CTSO Comparison
BDL vs CTSO Comparison
Compare BDL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDL
- CTSO
- Stock Information
- Founded
- BDL 1959
- CTSO 1997
- Country
- BDL United States
- CTSO United States
- Employees
- BDL N/A
- CTSO N/A
- Industry
- BDL Restaurants
- CTSO Medical/Dental Instruments
- Sector
- BDL Consumer Discretionary
- CTSO Health Care
- Exchange
- BDL Nasdaq
- CTSO Nasdaq
- Market Cap
- BDL 52.7M
- CTSO 61.7M
- IPO Year
- BDL N/A
- CTSO N/A
- Fundamental
- Price
- BDL $27.00
- CTSO $0.91
- Analyst Decision
- BDL
- CTSO Buy
- Analyst Count
- BDL 0
- CTSO 2
- Target Price
- BDL N/A
- CTSO $5.50
- AVG Volume (30 Days)
- BDL 1.1K
- CTSO 121.4K
- Earning Date
- BDL 08-12-2025
- CTSO 11-06-2025
- Dividend Yield
- BDL 2.00%
- CTSO N/A
- EPS Growth
- BDL 41.91
- CTSO N/A
- EPS
- BDL 2.32
- CTSO N/A
- Revenue
- BDL $201,851,000.00
- CTSO $36,107,520.00
- Revenue This Year
- BDL N/A
- CTSO $11.93
- Revenue Next Year
- BDL N/A
- CTSO $21.22
- P/E Ratio
- BDL $11.83
- CTSO N/A
- Revenue Growth
- BDL 8.84
- CTSO 20.18
- 52 Week Low
- BDL $22.61
- CTSO $0.71
- 52 Week High
- BDL $35.98
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- BDL 38.18
- CTSO 42.76
- Support Level
- BDL $26.63
- CTSO $0.94
- Resistance Level
- BDL $27.50
- CTSO $1.04
- Average True Range (ATR)
- BDL 0.51
- CTSO 0.05
- MACD
- BDL -0.28
- CTSO -0.00
- Stochastic Oscillator
- BDL 8.45
- CTSO 18.94
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.